Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
This drug is being developed by Novartis.
As of 2018[update], spartalizumab is undergoing Phase III trials.
[2] Immune activation: Dostarlimab Other: Ibalizumab
This monoclonal antibody–related article is a stub.